Get started
Work

Supplementary Figure 2 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 140K, Changes in subcellular markers induced by treatment with CUDC-101 or erlotinib in parental and erlotinib-TR HCC827 cells.
DOI: 10.1158/1535-7163.22500241
Authors: Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner, Cheng-Jung Lai
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362494043
Cites:
Cited by:
Related to: 10